Literature DB >> 23696925

Accumulation of the mutations in basal core promoter of hepatitis B virus subgenotype C1 increase the risk of hepatocellular carcinoma in Southern China.

Weihua Li1, Guangyuan Chen, Xianwen Yu, Yongying Shi, Miaoguan Peng, Jianjun Wei.   

Abstract

UNLABELLED: Hepatitis B virus (HBV) genotype C is associated with the development of hepatocellular carcinoma (HCC). In addition, HBV subgenotype C1 is the major subgenotype in Southern China. The aim of this study was to investigate whether there was the specific mutation patterns in HBV/C1 associated with Southern Chinese patients with HCC.
METHODS: Mutations in HBV basal core promoter (BCP) and their association with HCC were assessed in a matched cross-sectional control study of 102 HCC and 105 chronic hepatitis (CH) patients (from Guangdong, China) infected with HBV/C1. Functional analysis of HBx mutants was performed by the colony formation assay and the luciferase assays.
RESULTS: T1762/A1764 double mutations was frequently found in patients infected with HBV/C1, regardless of clinical status (64.7% in HCC and 51.4% in CH, P>0.05). Unexpectedly, the adjacent V1753 or A1768 mutation significantly increased the risk of HCC (P<0.05). Moreover, the prevalence of triple or quadruple mutations in BCP was significantly higher in patients with HCC than those with CH, particularly for HBeAg-positive-carriers (P<0.05). Functional analysis revealed that T1762/A1764 mutation alone did not alter the transcriptional activity and the inhibitory effects on cell proliferation of HBx, but triple or quadruple mutations largely abrogated this effect.
CONCLUSIONS: Accumulation of mutations involving V1753 or/and A1768 in addition to T1762/A1764 in BCP region were closely related to HCC among the patients infected with HBV/C1, particularly for HBeAg-positive-carriers. The increased risk of HCC caused by BCP variants may be attributable partially to modifying the biological functions of HBx.

Entities:  

Keywords:  Hepatitis B virus; X gene; basal core promoter; hepatocellular carcinoma; mutation

Mesh:

Substances:

Year:  2013        PMID: 23696925      PMCID: PMC3657360     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group.

Authors:  E Orito; M Mizokami; H Sakugawa; K Michitaka; K Ishikawa; T Ichida; T Okanoue; H Yotsuyanagi; S Iino
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

2.  [An epidemiologic study on the aetiological factors of primary liver cancer in Shunde City of Guangdong province].

Authors:  Z J Wang; Y P Zhou; B Cheng
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  1996-06

3.  Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.

Authors:  Yasuhito Tanaka; Motokazu Mukaide; Etsuro Orito; Man-Fung Yuen; Kiyoaki Ito; Fuat Kurbanov; Fuminaka Sugauchi; Yasuhiro Asahina; Namiki Izumi; Michio Kato; Ching-Lung Lai; Ryuzo Ueda; Masashi Mizokami
Journal:  J Hepatol       Date:  2006-08-10       Impact factor: 25.083

4.  Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China.

Authors:  Zhanhui Wang; Yasuhito Tanaka; Yuehua Huang; Fuat Kurbanov; Jinjun Chen; Guobing Zeng; Bin Zhou; Masashi Mizokami; Jinlin Hou
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

5.  Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan.

Authors:  Etsuro Orito; Fuminaka Sugauchi; Yasuhito Tanaka; Takafumi Ichida; Michio Sata; Eiji Tanaka; Takeshi Okanoue; Hiroshi Sakugawa; Hisatsuyo Watanabe; Hiroshi Miyakawa; Shuhei Nishiguchi; Hiromitsu Kumada; Ryuzo Ueda; Masashi Mizokami
Journal:  Intervirology       Date:  2005       Impact factor: 1.763

6.  Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues.

Authors:  H Tu; C Bonura; C Giannini; H Mouly; P Soussan; M Kew; P Paterlini-Bréchot; C Bréchot; D Kremsdorf
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

7.  Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

Authors:  Helene Norder; Anne-Marie Couroucé; Pierre Coursaget; José M Echevarria; Shou-Dong Lee; Isa K Mushahwar; Betty H Robertson; Stephen Locarnini; Lars O Magnius
Journal:  Intervirology       Date:  2004       Impact factor: 1.763

Review 8.  The core promoter of hepatitis B virus.

Authors:  A Kramvis; M C Kew
Journal:  J Viral Hepat       Date:  1999-11       Impact factor: 3.728

Review 9.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

10.  Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

Authors:  Sameer Parekh; Fabien Zoulim; Sang Hoon Ahn; Adrienne Tsai; Jisu Li; Shigenobu Kawai; Nasser Khan; Christian Trépo; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  14 in total

1.  Universal Primers for Detection and Sequencing of Hepatitis B Virus Genomes across Genotypes A to G.

Authors:  Jack Bee Chook; Woon Li Teo; Yun Fong Ngeow; Kok Keng Tee; Kee Peng Ng; Rosmawati Mohamed
Journal:  J Clin Microbiol       Date:  2015-03-18       Impact factor: 5.948

2.  Identification of hepatitis B virus X gene variants between hepatocellular carcinoma tissues and pericarcinoma liver tissues in Eastern China.

Authors:  Dan Wang; Hao Cai; Wen-Bo Yu; Long Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 3.  Key role of hepatitis B virus mutation in chronic hepatitis B development to hepatocellular carcinoma.

Authors:  Xin Zhang; Hui-Guo Ding
Journal:  World J Hepatol       Date:  2015-05-28

4.  Establishment and Characterization of an HBV Viral Spread and Infectious System following Long-Term Passage of an HBV Clinical Isolate in the Primary Human Hepatocyte and Fibroblast Coculture System.

Authors:  Yang Liu; Dmytro Kornyeyev; Lindsey May; Dong Han; Thomas Aeschbacher; Silvia Chang; Ross Martin; Hongmei Mo; Becket Feierbach
Journal:  J Virol       Date:  2022-08-29       Impact factor: 6.549

Review 5.  Core promoter: a critical region where the hepatitis B virus makes decisions.

Authors:  Jorge Quarleri
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

6.  HBV X gene point mutations are associated with the risk of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Yulan Wang; L I Zeng; Weiqing Chen
Journal:  Mol Clin Oncol       Date:  2016-04-05

Review 7.  Hepatitis B virus genotypes: global distribution and clinical importance.

Authors:  Mustafa Sunbul
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC.

Authors:  Xuefeng Gu; Maoying Fu; Yuqin Ding; Huihui Ni; Wei Zhang; Yanfang Zhu; Xiaojun Tang; Lin Xiong; Jiang Li; Liang Qiu; Jiaren Xu; Jin Zhu
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

9.  Hepatitis B viral replication influences the expression of natural killer cell ligands.

Authors:  Lemonica Koumbi; Teresa Pollicino; Giovanni Raimondo; Naveenta Kumar; Peter Karayiannis; Salim I Khakoo
Journal:  Ann Gastroenterol       Date:  2016-04-25

10.  Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study.

Authors:  Mingsheng Huang; Qu Lin; Haofan Wang; Junwei Chen; Mingjun Bai; Long Wang; Kangshun Zhu; Zaibo Jiang; Shouhai Guan; Zhengran Li; Jiesheng Qian; Mingan Li; Pengfei Pang; Hong Shan
Journal:  Eur Radiol       Date:  2016-01-20       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.